Spexis Announces Changes to the Executive Committee

Spexis AG / Key word(s): Personnel/Personnel
Spexis Announces Changes to the Executive Committee

01-Nov-2023 / 07:20 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement pursuant to Art. 53 LR

Spexis Announces Changes to the Executive Committee

Allschwil, Switzerland, November 1, 2023

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on
macrocycle therapeutics for rare diseases and oncology, today announced that
Hernan Levett, currently Chief Financial Officer, has decided to pursue a
new career opportunity outside the company. He will continue to support the
company as a strategic advisor on financial transactions and will depart the
company effective December 1, 2023. Martin Jakobovic, currently Head of
Finance, will succeed Hernan Levett as interim Chief Financial Officer
joining the Executive Committee on December 1, 2023. Additionally, Muriel
Fleming, currently Head of Human Resources, will assume additional
responsibilities related to administration and facilities, as well as
joining the Executive Committee of Spexis also on December 1, 2023.

"On behalf of the entire Spexis team and the board of directors, I would
like to thank Hernan for his dedication and contributions to the company
since its inception in December 2021," said Jeff Wager, M.D., Chairman & CEO
of Spexis. "Hernan has been a very valuable member of the management team
and we wish him all the best in his future endeavors. I look forward to
collaborating with Martin, whose leadership skills and knowledge of the
company will prove invaluable in achieving our current goals. I would also
like to congratulate Muriel on her appointment to the Executive Committee
where she will continue to provide important insight on Spexis' corporate
strategy and development efforts."

"After being intimately involved in the formation of Spexis and as Chief
Financial Officer since, it is time for me to take on a new challenge,"
remarked Hernan Levett. "I would like to thank Jeff, the board of directors,
our shareholders, and the entire Spexis team for their trust, support, and
commitment. It has been a pleasure to serve the company and I wish the team
all the best as they move into an exciting chapter in the company's future."

Biographical summaries of Martin and Muriel can be found on our website
www.spexisbio.com

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in
Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases
and oncology. For further information please visit: www.spexisbio.com.

For further information please contact:

For Investors:

     Stephen Jasper
     Managing Director
     Gilmartin Group
     (1)stephen@gilmartinir.com

For Media:

     Dr. Stephan Feldhaus
     Feldhaus & Partner
     +41 79 865 92 56
     (2)feldhaus@feldhaus-partner.ch

     1. mailto:stephen@gilmartinir.com
     2. mailto:feldhaus@feldhaus-partner.ch

Disclaimer

This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


---------------------------------------------------------------------------

End of Inside Information

---------------------------------------------------------------------------

   Language:       English
   Company:        Spexis AG
                   Hegenheimermattweg 125
                   4123 Allschwil
                   Switzerland
   Phone:          +41 61 567 1600
   Fax:            +41 61 567 1601
   E-mail:         info@spexisbio.com
   Internet:       www.spexisbio.com
   ISIN:           CH0106213793
   Valor:          SPEX
   Listed:         SIX Swiss Exchange
   EQS News ID:    1762049

End of Announcement EQS News Service
---------------------------------------------------------------------------

1762049 01-Nov-2023 CET/CEST